Itamar Medical Ltd (ITMMF) 0.7100 $ITMMF
Philips Respironics GK Unveils a New Model of a Portable Sleep Diagnostic Device "WatchPAT(TM)"
Business Wire - Wed Apr 02, 8:02AM CDT
Philips Respironics GK (Headquartered in Minato Ward of Tokyo, hereafter Philips, CEO Danny Risberg) announced today that, beginning April 1, 2014, they are starting sales of a portable sleep diagnostic device WatchPAT(TM) (made by Itamar Medical Ltd., Caesarea, Israel) .
Thorne Research, Inc, WellnessFX, And Itamar Medical, Maker Of The EndoPAT® And WatchPAT® Medical Devices, Enter Into 3-Year Co-Marketing Agreement
PR Newswire - Thu Jan 23, 8:57AM CST
Thorne Research, Inc., a leader in developing and manufacturing pure, high-quality nutritional supplements marketed through licensed healthcare practitioners, today announced that the company has entered into a three-year non-exclusive co-marketing agreement with Itamar Medical, Inc., to market Itamar's EndoPAT®, a unique, proprietary, FDA-cleared medical device for the assessment of arterial (endothelial) function, and WatchPAT®, a unique home-based sleep test to diagnose obstructive sleep apnea.
Helping New Yorkers Prevent Heart Attacks: Itamar Medical Joins The Fight With New Campaign
PR Newswire - Fri Nov 08, 7:00AM CST
In response to the disturbing fact that people are more likely to die of a heart attack in New York City than anywhere else in the U.S., medical device company Itamar Medical (TASE: ITMR), today announced the launch of its first-ever initiative in the U.S. to increase awareness of endothelial (arterial) function testing and the importance of early detection in preventing heart attacks, particularly for symptomatic patients. The New York area was selected as the first city to kick off "Don't Ignore Your EndoScore" The campaign rolls out in New York the week of November 11.
Somnoware Healthcare Systems Partners with Itamar Medical to Offer Optimized Sleep Disorder Diagnosis and Treatment
PRWeb - Wed Jul 03, 7:31AM CDT
Reflecting an ongoing commitment to optimizing workflow and enabling better coordination of care for sleep apnea patients, Itamar Medical Ltd. and Somnoware Healthcare Systems, Inc. (Somnoware) announced a strategic alliance based on a shared vision for the sleep industry. According to leadership from both companies, aligning at the technology, marketing and business levels will drive new growth opportunities and increase their collective potential to transform delivery of care, reduce cost, and improve productivity for all stakeholders involved in the management of sleep apnea.
Itamar-Medical Appoints Gilad Glick as CEO; Transitioning from Current Role as Vice President Worldwide Sales and Marketing of Johnson & Johnson's Cardio Division
Business Wire - Mon May 20, 7:00AM CDT
En route to commercial acceleration: Itamar Medical has announced the appointment of Gilad Glick as the company CEO, effective July 1st 2013. Dr. Dov Rubin, who served as CEO for the past five years, will step down.
Philips Respironics GK Unveils a New Model of a Portable Sleep Diagnostic Device "WatchPAT(TM)"
Business Wire - Wed Apr 02, 8:02AM CDT
Philips Respironics GK (Headquartered in Minato Ward of Tokyo, hereafter Philips, CEO Danny Risberg) announced today that, beginning April 1, 2014, they are starting sales of a portable sleep diagnostic device WatchPAT(TM) (made by Itamar Medical Ltd., Caesarea, Israel) .
Thorne Research, Inc, WellnessFX, And Itamar Medical, Maker Of The EndoPAT® And WatchPAT® Medical Devices, Enter Into 3-Year Co-Marketing Agreement
PR Newswire - Thu Jan 23, 8:57AM CST
Thorne Research, Inc., a leader in developing and manufacturing pure, high-quality nutritional supplements marketed through licensed healthcare practitioners, today announced that the company has entered into a three-year non-exclusive co-marketing agreement with Itamar Medical, Inc., to market Itamar's EndoPAT®, a unique, proprietary, FDA-cleared medical device for the assessment of arterial (endothelial) function, and WatchPAT®, a unique home-based sleep test to diagnose obstructive sleep apnea.
Helping New Yorkers Prevent Heart Attacks: Itamar Medical Joins The Fight With New Campaign
PR Newswire - Fri Nov 08, 7:00AM CST
In response to the disturbing fact that people are more likely to die of a heart attack in New York City than anywhere else in the U.S., medical device company Itamar Medical (TASE: ITMR), today announced the launch of its first-ever initiative in the U.S. to increase awareness of endothelial (arterial) function testing and the importance of early detection in preventing heart attacks, particularly for symptomatic patients. The New York area was selected as the first city to kick off "Don't Ignore Your EndoScore" The campaign rolls out in New York the week of November 11.
Somnoware Healthcare Systems Partners with Itamar Medical to Offer Optimized Sleep Disorder Diagnosis and Treatment
PRWeb - Wed Jul 03, 7:31AM CDT
Reflecting an ongoing commitment to optimizing workflow and enabling better coordination of care for sleep apnea patients, Itamar Medical Ltd. and Somnoware Healthcare Systems, Inc. (Somnoware) announced a strategic alliance based on a shared vision for the sleep industry. According to leadership from both companies, aligning at the technology, marketing and business levels will drive new growth opportunities and increase their collective potential to transform delivery of care, reduce cost, and improve productivity for all stakeholders involved in the management of sleep apnea.
Itamar-Medical Appoints Gilad Glick as CEO; Transitioning from Current Role as Vice President Worldwide Sales and Marketing of Johnson & Johnson's Cardio Division
Business Wire - Mon May 20, 7:00AM CDT
En route to commercial acceleration: Itamar Medical has announced the appointment of Gilad Glick as the company CEO, effective July 1st 2013. Dr. Dov Rubin, who served as CEO for the past five years, will step down.
